We're proud to announce the launch of CobiCure LLC, a not-for-profit focused on curing rare, life-threatening diseases in children. Initial collaborators include healthcare investment firm, Deerfield Management and medtech innovator, Coridea. prnewswire.com/news-releases/…

Andrew ElBardissi, MD, a partner at Deerfield Management shares inspiration for the creation of CobiCure. advanciumhealth.org/cobicure.html

CobiCure is based in New York City and is a resident of the Cure, a healthcare innovation campus located in Manhattan. For more information on CobiCure, visit bit.ly/3OIA0Gh

CobiCure’s first investment will focus on the development and commercialization of a medical device for the congenital heart condition, functional single ventricle (FSV) disorder. The device in development was licensed from Transmural Systems. prnewswire.com/news-releases/…

CobiCure was launched through Advancium, an organization dedicated to advancing healthcare services and equity. Advancium supports new ideas, organizations, and initiatives that address underserved patient populations and difficult-to-treat diseases. advanciumhealth.org

2,000 children a year are born w/ a Functional Single Ventricle. Potential solutions have been traditionally underfunded due to a small commercial market. CobiCure's first investment focuses on the development of a medical device for this heart condition. cobicure.org

Speaking to Medtech Insight, Citeline Commercial, one of CobiCure’s founders, Howard Levin explained that the current treatments for FSV disorder are limited. Levin is also CEO of the Deerfield Catalyst, a subsidiary of Deerfield Management and the president of Coridea. medtech.pharmaintelligence.informa.com/MT145658/CobiC…

By leveraging a for-profit model with philanthropic investments, CobiCure will provide a viable path to commercialization of life-saving medical devices and other technological innovations. Learn more about CobiCure’s work with Transmural Systems prnewswire.com/news-releases/…

CobiCure is a resident of the Cure at 345 Park Avenue South, a premier healthcare innovation campus located in New York City. As a resident of Cure, CobiCure will have access to leading-edge technology, equipment, and other important resources. cobicure.org

The first condition CobiCure is targeting is functional single ventricle (FSV) disorder. FSV disorder is a rare condition where one of the two ventricles of the heart are malformed, preventing effective pumping of blood. medtech.pharmaintelligence.informa.com/MT145658/CobiC…

Driven by a deep understanding of the pediatric healthcare market and a passion for bringing life changing technologies to address gaps in care, CobiCure has an initial focus on pediatric cardiovascular conditions Learn more at cobicure.org

#ICYMI Mark Veich, President of the Advancium Health Network, interim President of CobiCure, and Executive Director, Deerfield Foundation presented at CSI Frankfurt.

“I feel a lot of pride for our bold mission to cure rare and life-threatening diseases in children. ” – Mark Veich, President of the Advancium Health Network, interim President of CobiCure medium.com/authority-maga…

CobiCure will leverage Deerfield Management's expertise and insights as well as Coridea, a for-profit medical device incubator focused on solutions for cardiac, pulmonary, renal, and neurology conditions. cobicure.org

Advancium is pleased to announce a $30M charitable gift from the Maxine and Stuart Frankel Foundation, of Bloomfield Hills, MI. Of the total contribution, $5M will be allocated to support the activities of CobiCure. prnewswire.com/news-releases/…